Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
34 hedge funds and large institutions have $4.32M invested in Regulus Therapeutics in 2020 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
21% more funds holding
Funds holding: 28 → 34 (+6)
9% more capital invested
Capital invested by funds: $3.97M → $4.32M (+$344K)
1.8% less ownership
Funds ownership: 4.1% → 2.3% (-1.8%)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$35.1K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$28.9K |
| 3 |
SG Americas Securities
New York
|
+$22.9K |
| 4 |
Jane Street
New York
|
+$13.2K |
| 5 |
GC
Grimes & Company
Westborough,
Massachusetts
|
+$12.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$870K |
| 2 |
Renaissance Technologies
New York
|
-$145K |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$129K |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$93.5K |
| 5 |
Rockefeller Capital Management
New York
|
-$39K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DY
26
Dowling & Yahnke
San Diego,
California
| $8K | +$7.85K | +1,200 | New |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $5K | – | – | – |
|
|
VFA
28
Valeo Financial Advisors
Carmel,
Indiana
| $2K | – | – | – |
|
29
UBS Group
Zurich,
Switzerland
| $1K | +$589 | +90 | New |
|
|
FDCDDQ
30
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $113 | – | – | – |
|
|
EC
31
EcoR1 Capital
San Francisco,
California
| – | -$870K | -188,681 | Closed |
|
|
CH
32
CVI Holdings
Wilmington,
Delaware
| – | -$129K | -28,015 | Closed |
|
|
33
Rockefeller Capital Management
New York
| – | -$39K | -8,464 | Closed |
|
|
WOC
34
West Oak Capital
Westlake Village,
California
| – | -$3K | -700 | Closed |
|
35
Victory Capital Management
San Antonio,
Texas
| – | -$2K | -583 | Closed |
|
36
Morgan Stanley
New York
| – | +$412 | +63 | +630% |
|
RGLS Hedge Fund Activity: Q2 2020 in Review
34 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2020, worth a combined $4.32M — up 8.7% from $3.97M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RGLS positions and 6 closed out — a net gain of 6 holders — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $35.1K. The largest seller was EcoR1 Capital, exiting entirely with an estimated $870K sold.
- 34 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2020, up from 28 in Q1 2020.
- Funds reported $4.32M of Regulus Therapeutics stock for Q2 2020, up 8.7% quarter-over-quarter.
- 12 funds opened new Regulus Therapeutics positions in Q2 2020 and 6 closed out, a net change of +6 holders.
- The largest Regulus Therapeutics buyer in Q2 2020 was Millennium Management, an estimated $35.1K added.
- The largest Regulus Therapeutics seller in Q2 2020 was EcoR1 Capital, an estimated $870K sold.
Based on aggregated 13F filings for Q2 2020.